SOURCE: Lipomics Technologies, Inc.

February 14, 2007 09:30 ET

Lipomics Technologies to Support Isis Pharmaceuticals in Preclinical and Clinical Studies of Metabolic Drug Candidates

Lipomics Expects to Develop Diagnostic Panels Based on Results of Clinical Trial Testing

WEST SACRAMENTO, CA -- (MARKET WIRE) -- February 14, 2007 -- Lipomics Technologies, Inc., a privately held company that specializes in the analysis of lipid metabolites, announced today that it has entered into an agreement with Isis Pharmaceuticals, Inc. to provide lipid-focused support of preclinical and clinical trial testing for various compounds to treat metabolic disease.

Lipomics will retain exclusive rights to develop diagnostic applications based on the data from the studies, while Isis will retain all therapeutic rights. Lipomics seeks to partner with drug companies that see the value in developing companion diagnostic tests that increase the efficacy, safety and cost-effectiveness of a therapeutic.

Sanjay Bhanot, Vice President, Metabolic Diseases R&D at Isis, commented, "We are impressed with Lipomics' capabilities and look forward to working with them as we assess the lipid profiles of compounds we have in our metabolic disease development pipeline."

"We look forward to working with Isis. We believe our approach, which focuses on providing plasma-based mechanistic markers of lipid metabolism, will help to advance their compounds through the clinic," said Steve Watkins, president and chief scientific officer at Lipomics.

About Lipomics

Lipomics Technologies provides industry-leading metabolic assessments for drug research, clinical diagnostics and personalized medicine. The Company's proprietary analytical technologies generate comprehensive, accurate and quantitative profiles of lipid metabolites.

A broad range of bioinformatics and analytical tools map these profiles to the underlying biochemical pathways. Through these tools, Lipomics delivers deep and rich knowledge about biological and metabolic changes induced by disease, drug action, nutritional or lifestyle influences.

In partnership with pharmaceutical, biotechnology and nutrition companies, Lipomics uses its technologies to discover new diagnostic biomarkers, improve drug discovery, develop companion diagnostics and enable individualized health management.

More information about Lipomics can be found at

Contact Information


    Sarina Chohan
    (916) 371-7974
    Email Contact

    Agency Contact
    Doug Forsyth
    Alchymia Communications®
    (541) 482-8744
    Email Contact